Topics

Pediatric CNS tumors | Treatment | Clinical trials | CAR-T-cells

Home > Publications > Topics > Pediatric CNS tumors > Treatment > Clinical trials > CAR-T-cells

Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B.
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
J Clin Oncol. 2024 May 21:JCO2302019. doi: 10.1200/JCO.23.02019. PMID: 38771986. Interventional study. ˍ

Gust J, Cole BL, Ronsley R, Wilson AL, Seidel K, Wendler J, Pattabhi S, Brown C, Rawlings-Rhea SD, Shtanukhina N, Browd SR, Hauptman JS, Lee A, Ojemann JG, Crotty EE, Leary SES, Perez FA, Wright JN, Albert CM, Pinto N, Gardner RA, Vitanza NA, Jensen MC, Park JR.
Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial.
Neuro Oncol. 2025 Mar 12:noaf064. doi: 10.1093/neuonc/noaf064. PMID: 40070357. Interventional study˰ ˍ